Literature DB >> 6284507

Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virus.

L Skriver, L S Nielsen, R Stephens, K Danø.   

Abstract

We have previously reported the purification of a plasminogen-activating serine protease with an approximate Mr of 48 000 from sarcoma-virus-transformed murine cells. We now report that under serum-free conditions the enzyme is released from the cells in an inactive form. After affinity chromatography with 4-aminobenzamidine-cellulose, ion-exchange chromatography and gel filtration, the proenzyme could be obtained from culture fluid as a pure, homogeneous protein as evaluated by polyacrylamide gel electrophoresis with sodium dodecylsulphate. Proenzyme was quantitatively converted to active enzyme by incubation with catalytic amounts of plasmin. Analysis by polyacrylamide gel electrophoresis with sodium dodecylsulphate under reducing and non-reducing conditions showed that the inactive form consisted of a single polypeptide chain with an Mr of approximately 48 000, while the active form consisted of two chains with Mr values of approximately 18 000 and 29 000 , held together by one or more disulphide bridges. The active-site reagent diisopropylfluorophosphate in radiolabelled form was incorporated into the 29 000-Mr chain of the active enzyme, but not into the inactive form. These findings provide conclusive evidence for the existence of an inactive proenzyme to this plasminogen activator and thus demonstrate and additional step in a cascade-like reaction leading to extracellular proteolysis. Regulatory as well as methodological implications of this findings are discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6284507     DOI: 10.1111/j.1432-1033.1982.tb06608.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  20 in total

1.  Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.

Authors:  Kenneth A Botkjaer; Sarah Fogh; Erin C Bekes; Zhuo Chen; Grant E Blouse; Janni M Jensen; Kim K Mortensen; Mingdong Huang; Elena Deryugina; James P Quigley; Paul J Declerck; Peter A Andreasen
Journal:  Biochem J       Date:  2011-08-15       Impact factor: 3.857

Review 2.  The role of the integrin vitronectin receptor, alpha v beta 3 in melanoma metastasis.

Authors:  J Nip; P Brodt
Journal:  Cancer Metastasis Rev       Date:  1995-09       Impact factor: 9.264

3.  Co-inoculation of human and murine carcinoma cells induces reciprocal suppression of metastasis by both cell lines.

Authors:  S M Nielsen-Preiss; J P Quigley; J E Testa
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

4.  Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation.

Authors:  Sergei Zaitsev; Dirk Spitzer; Juan-Carlos Murciano; Bi-Sen Ding; Samira Tliba; M Anna Kowalska; Oscar A Marcos-Contreras; Alice Kuo; Victoria Stepanova; John P Atkinson; Mortimer Poncz; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2010-04-21       Impact factor: 22.113

5.  The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.

Authors:  Niels Behrendt; Karin List; Peter A Andreasen; Keld Danø
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

6.  Plasmin induces acantholysis in skin organ cultures.

Authors:  T Hunziker; J D Vassalli
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

7.  Secretion of plasminogen activators by human colorectal and gastric tumor explants.

Authors:  S R Harvey; D D Lawrence; J M Madeja; S J Abbey; G Markus
Journal:  Clin Exp Metastasis       Date:  1988 Nov-Dec       Impact factor: 5.150

8.  Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one-step affinity purification.

Authors:  L S Nielsen; J G Hansen; P A Andreasen; L Skriver; K Danø; J Zeuthen
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

9.  Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody.

Authors:  P A Andreasen; L S Nielsen; J Grøndahl-Hansen; L Skriver; J Zeuthen; R W Stephens; K Danø
Journal:  EMBO J       Date:  1984-01       Impact factor: 11.598

10.  Tumor promoter PMA stimulates the synthesis and secretion of mouse pro-urokinase in MSV-transformed 3T3 cells: this is mediated by an increase in urokinase mRNA content.

Authors:  D Belin; F Godeau; J D Vassalli
Journal:  EMBO J       Date:  1984-08       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.